Dosing & Uses
Dosage Forms & Strengths
powder for injection
- 180mg/vial (150mg/mL after reconstitution)
Cryopyrin-Associated Periodic Syndrome
Indicated for treatment of cryopyrin-associated periodic syndrome (CAPS), including familial old autoinflammatory syndrome and Muckle-Wells syndrome in adults and children
>40 kg: 150 mg SC q8wk
15-40 kg: 2 mg/kg SC q8wk; may increase to 3 mg/kg if inadequate response
Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Indicated for the treatment of Tumor Necrosis Factor (TNF) receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
150 mg SC q4wk; may increase to 300 mg q4wk if the clinical response is not adequate
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency
Indicated for the treatment of hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS) (HIDS)/mevalonate kinase deficiency (MKD) in adult and pediatric patients
150 mg SC q4wk; may increase to 300 mg q4wk if the clinical response is not adequate
Familial Mediterranean Fever
Indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients
150 mg SC q4wk; may increase to 300 mg q4wk if the clinical response is not adequate
Still Disease
Indicated for the treatment of active Still disease, including adult-onset Still disease (AOSD)
4 mg/kg SC q4Weeks; not to exceed 300 mg/dose
Dosage Forms & Strengths
powder for injection
- 180mg/vial (150mg/mL after reconstitution)
Cryopyrin-Associated Periodic Syndrome
Indicated for treatment of cryopyrin-associated periodic syndrome, including familial old autoinflammatory syndrome and Muckle-Wells syndrome in adults and children
<4 years
- Safety and efficacy not established
≥4 Years
Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Indicated for the treatment of Tumor Necrosis Factor (TNF) receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients
≤40 kg: 2 mg/kg SC q4wk; may increase to 4 mg/kg q4wk if the clinical response is not adequate
>40 kg: 150 mg SC q4wk; may increase to 300 mg q4wk if the clinical response is not adequate
Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency
Indicated for the treatment of hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS) (HIDS)/mevalonate kinase deficiency (MKD) in adult and pediatric patients
≤40 kg: 2 mg/kg SC q4wk; may increase to 4 mg/kg q4wk if the clinical response is not adequate
>40 kg: 150 mg SC q4wk; may increase to 300 mg q4wk if the clinical response is not adequate
Familial Mediterranean Fever
Indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients
≤40 kg: 2 mg/kg SC q4wk; may increase to 4 mg/kg q4wk if the clinical response is not adequate
>40 kg: 150 mg SC q4wk; may increase to 300 mg q4wk if the clinical response is not adequate
Systemic Juvenile Idiopathic Arthritis
Indicated for Still disease and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older
<2 years: Safety and efficacy not established
≥2 years and weight ≥7.5 kg: 4 mg/kg SC q4Weeks; not to exceed 300 mg/dose
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Nasopharyngitis (34%)
Diarrhea (20%)
Influenza (17%)
Rhinitis (17%)
Headache (14%)
Nausea (14%)
Vertigo (9-14%)
Gastroenteritis (11%)
Pharyngitis (11%)
Weight increase (11%)
Bronchitis (11%)
Musculoskeletal pain (11%)
WBC count ≤0.8x LLN (10.4%)
1-10%
Injection site pain (9%)
Decreased platelets (6.3%)
ANC <1x 109/L (6%)
Increased AST/ALT (4.1%)
Frequency Not Defined
Mild bilirubin elevation
Warnings
Contraindications
Hypersensitivity
Cautions
Risk of serious infections, including opportunistic infections and reactivation of latent hepatitis or TB; interrupt therapy if serious infection develops; infections, predominantly of upper respiratory tract, in some instances serious, reported in isolated cases of unusual or opportunistic infections including aspergillosis, atypical mycobacterial infections, cytomegalovirus, herpes zoster; causal relationship of therapy to infections cannot be excluded
Hypersensitivity reported postmarketing; disease symptoms may be similar to symptoms of hypersensitivity; if a severe hypersensitivity reaction occurs, therapy should be discontinued and appropriate therapy initiated
May impair defenses against malignancies
Macrophage activation syndrome (MAS) is a life-threatening disorder that may develop with rheumatic conditions, particularly with Still disease or SJIA; it should be aggressively treated; it is important to be attentive to symptoms of infection or worsening of Still’s disease, as these are known triggers for MAS; based on clinical trials, canakinumab did not increase incidence of MAS;
Drug interaction overview
-
IL-1 or TNF blockers
- Avoid coadministration
- Coadministration with other IL-1 antagonists or TNF inhibitors increases risk of neutropenia and serious infection
-
Live vaccines
- Avoid coadministration
- Data are not available on effects of live vaccination or secondary infection transmission by live vaccines if administered while on canakinumab
- Recommended to complete immunization before initiating canakinumab
-
CYP450 substrates
- CYP450 enzymes are suppressed by increased levels of cytokines (eg, IL-1) during chronic inflammation
- CYP450 enzymes are expected to normalize once IL-1 levels decrease
- Monitor CYP450 substrates with narrow therapeutic indices, where the dose is individually adjusted (eg, warfarin); dose adjustment may be necessary
Pregnancy & Lactation
Pregnancy
Limited human data from postmarketing reports on use in pregnant women are not sufficient to inform a drug associated risk
Monoclonal antibodies, such as canakinumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential fetal exposure is likely to be greater during the second and third trimesters of pregnancy
Animal data
- Studies with marmoset monkeys showed no evidence of embryotoxicity or fetal malformations with during organogenesis and later in gestation at doses that produced exposures ~11 times the exposure at the maximum recommended human dose (MRHD) and greater
- Delays in fetal skeletal development were observed in marmoset monkeys following prenatal exposure at concentrations ~11 times the MRHD and greater; similar delays in fetal skeletal development were observed in mice administered a murine analog of canakinumab during organogenesis
Lactation
Data are not available regarding presence in human milk, effects on breastfed infants, or effects on milk production
Human IgG is known to be present in human milk; effects of canakinumab in breast milk and possible systemic exposure in the breastfed infant are unknown; the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed infant from therapy or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Recombinant, human monoclonal antibody that binds to human interleukin (IL)-1β and neutralizes its activity by blocking its interaction with IL-1 receptors; does not bind IL-1α or IL-1 receptor antagonist (IL-1ra)
Absorption
Absolute bioavailability: 66%
Peak plasma concentration: 16 mcg/mL
Peak plasma time
- Adults: ~7 days
- Pediatric patients: 2-7 days
Distribution
Vd (steady-state)
- CAPS (70-kg patient): 6.01 L
- SJIA (33-kg patient): 3.2 L
- Periodic fever syndrome (70-kg patient): 6.34 L
Elimination
Clearance
- CAPS (70-kg patient): 0.174 L/day
- SJIA (33-kg patient): 0.11 L/day
- Periodic fever syndrome (70-kg patient): 0.17 L/day
Half-life
- Adults, 150-mg dose: 26 days
- Children and adolescents, 150-mg or 2-mg/kg dose: 22.9-25.7 days
Administration
SC Preparation
Reconstitute lyophilized powder with 1 mL sterile water for injection to obtain 150 mg/mL solution
Swirl the vial slowly at an angle of about 45° for ~1 minute and allow to stand for 5 minutes
Do not shake; gently turn the vial upside down and back again 10 times; avoid touching the rubber stopper with your fingers
Allow stand for 15 minutes at room temperature
Do not shake
Do not use if particulate matter is present in the solution
Tap the side of the vial to remove any residual liquid from the stopper
The reconstituted solution should be clear to opalescent, colorless to a slightly brownish yellow tint, and essentially free from particulates
If the solution has a distinctly brown discoloration, do not use
Slight foaming of the product upon reconstitution is not unusual
Protect from light
Reconstituted solution can be kept at room temperature if used within 1 hr; otherwise, refrigerate at 2-8°C (36-46°F) and use within 4 hr
SC Administration
Using a sterile 1-mL syringe and needle, carefully withdraw the required volume depending on the dose to be administered and inject SC using a 27-gauge x 0.5-inch needle
Avoid injecting scar tissue as this may result in insufficient exposure
Discard any unused product or waste material in accordance with local requirements
Storage
Unopened vial
- Refrigerate at 2-8°C (36-46° F)
- Do not freeze
- Store in the original carton to protect from light
Reconstituted vial
- Room temperature if used within 1 hr; otherwise, refrigerate at 2-8°C (36-46°F) and use within 4 hr
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.